Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Melanoma 39Neoplasms 16Neoplasm Metastasis 8Colorectal Neoplasms 5Thyroid Neoplasms 3Skin Neoplasms 2Recurrence 2Leukemia, Hairy Cell 2Wilms Tumor 1Urinary Bladder Neoplasms 1Thyroid cancer, follicular 1Thyroid Cancer, Papillary 1Skin Diseases 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Pancreatic Neoplasms 1Osteosarcoma 1Noonan syndrome 3 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasms, Unknown Primary 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Histiocytosis, Langerhans-Cell 1Heterotaxy Syndrome 1Hepatoblastoma 1Glioma 1

Interventions

Gemcitabine 35Cisplatin 21Capecitabine 17Oxaliplatin 16Leucovorin 11Fluorouracil 11pembrolizumab 8S 1 (combination) 8Nivolumab 6tremelimumab 5durvalumab 5Bevacizumab 5lenvatinib 4Irinotecan 4trametinib 3titanium silicide 3atezolizumab 3Radiofrequency Ablation 3zanidatamab 2vandetanib 2irinotecan sucrosofate 2derazantinib 2camrelizumab 2binimetinib 2apatinib 2Trastuzumab 2Tegafur 2Radiotherapy 2Panitumumab 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Biliary Tract Neoplasms × Vemurafenib × Clear all
NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Genentech, Inc.

Phase 2 Completed
673 enrolled 22 charts
GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡